HomeCompareRAONF vs KMB

RAONF vs KMB: Dividend Comparison 2026

RAONF yields 76.92% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAONF wins by $1.40M in total portfolio value
10 years
RAONF
RAONF
● Live price
76.92%
Share price
$2.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.45M
Annual income
$406,212.55
Full RAONF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — RAONF vs KMB

📍 RAONF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAONFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAONF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RAONF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAONF
Annual income on $10K today (after 15% tax)
$6,538.46/yr
After 10yr DRIP, annual income (after tax)
$345,280.67/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, RAONF beats the other by $340,841.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAONF + KMB for your $10,000?

RAONF: 50%KMB: 50%
100% KMB50/50100% RAONF
Portfolio after 10yr
$745.5K
Annual income
$205,717.44/yr
Blended yield
27.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

RAONF
No analyst data
Altman Z
259.5
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAONF buys
0
KMB buys
0
No recent congressional trades found for RAONF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAONFKMB
Forward yield76.92%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$1.45M$45.9K
Annual income after 10y$406,212.55$5,222.34
Total dividends collected$1.25M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RAONF vs KMB ($10,000, DRIP)

YearRAONF PortfolioRAONF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$18,392$7,692.31$11,314$614.45+$7.1KRAONF
2$32,902$13,222.36$12,867$760.19+$20.0KRAONF
3$57,311$22,106.15$14,713$945.27+$42.6KRAONF
4$97,310$35,987.08$16,924$1,181.90+$80.4KRAONF
5$161,228$57,105.82$19,596$1,486.64+$141.6KRAONF
6$260,939$88,425.56$22,850$1,882.16+$238.1KRAONF
7$412,955$133,749.94$26,849$2,399.80+$386.1KRAONF
8$639,683$197,821.28$31,812$3,083.36+$607.9KRAONF
9$970,847$286,385.73$38,033$3,994.72+$932.8KRAONF
10$1,445,019$406,212.55$45,918$5,222.34+$1.40MRAONF

RAONF vs KMB: Complete Analysis 2026

RAONFStock

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Full RAONF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this RAONF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAONF vs SCHDRAONF vs JEPIRAONF vs ORAONF vs KORAONF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.